AR071885A1 - Proteinas de union al receptor de interleuquina 21 - Google Patents
Proteinas de union al receptor de interleuquina 21Info
- Publication number
- AR071885A1 AR071885A1 ARP090101847A ARP090101847A AR071885A1 AR 071885 A1 AR071885 A1 AR 071885A1 AR P090101847 A ARP090101847 A AR P090101847A AR P090101847 A ARP090101847 A AR P090101847A AR 071885 A1 AR071885 A1 AR 071885A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen binding
- proteins
- disorders
- interleuquine
- union
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004527 Interleukin-21 Receptors Human genes 0.000 abstract 5
- 108010017411 Interleukin-21 Receptors Proteins 0.000 abstract 5
- 102000023732 binding proteins Human genes 0.000 abstract 4
- 108091008324 binding proteins Proteins 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101001010593 Homo sapiens Interleukin-21 receptor Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000047008 human IL21R Human genes 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente solicitud proporciona prote¡nas de union y sus fragmentos de union ant¡geno, que se unen espec¡ficamente al receptor humano interleuquina-21 (IL-21R). Las prote¡nas de union pueden actuar como, por ejemplo, antagonistas de la actividad IL-21R, por lo tanto modulando respuestas inmunes en general, y aquellas mediadas por IL-21R en particular. Las composiciones y metodos divulgados se pueden utilizar, por ejemplo, para diagnosticar y/o tratar trastornos asociados con IL-21R, por ejemplo, trastornos inflamatorios, trastornos auto-inmunologicos, alergias, rechazos de transplantes, c ncer, y otros trastornos del sistema inmunologico. Reivindicacion 1: Una prote¡na de union aislada o un fragmento de union ant¡geno de la misma que se une a IL-21R, en donde la prote¡na de union o su fragmento de union ant¡geno comprende al menos una secuencia de amino cidos que es al menos aproximadamente 95% identica con una secuencia de amino cidos seleccionada del grupo que consiste de ID de SEC Nø: 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 165-168, 171-193, 213-229, 240, 242, 244, 246 y 248.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5550008P | 2008-05-23 | 2008-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071885A1 true AR071885A1 (es) | 2010-07-21 |
Family
ID=41112652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101847A AR071885A1 (es) | 2008-05-23 | 2009-05-22 | Proteinas de union al receptor de interleuquina 21 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8163884B2 (es) |
| EP (1) | EP2297199A1 (es) |
| JP (1) | JP2011523849A (es) |
| KR (1) | KR20110040773A (es) |
| CN (1) | CN102105491A (es) |
| AR (1) | AR071885A1 (es) |
| AU (1) | AU2009248809A1 (es) |
| CA (1) | CA2724915A1 (es) |
| CL (1) | CL2009001284A1 (es) |
| CO (1) | CO6382184A2 (es) |
| IL (1) | IL209328A0 (es) |
| MX (1) | MX2010012811A (es) |
| MY (1) | MY149448A (es) |
| NZ (1) | NZ589330A (es) |
| PE (1) | PE20100141A1 (es) |
| RU (1) | RU2010152690A (es) |
| SA (1) | SA109300315B1 (es) |
| TW (1) | TW201000129A (es) |
| WO (1) | WO2009143523A1 (es) |
| ZA (1) | ZA201008335B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| EP2518084B1 (en) * | 2009-12-25 | 2016-11-30 | Sekisui Medical Co., Ltd. | Method for measuring human insulin and measurement reagent |
| ES2628841T3 (es) * | 2010-03-12 | 2017-08-04 | Alexion Pharmaceuticals, Inc. | Proteínas de fusión npp1 |
| US9309318B2 (en) * | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
| WO2018045273A2 (en) * | 2016-09-02 | 2018-03-08 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating neoplasias |
| CA3096821A1 (en) | 2017-09-27 | 2019-04-04 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US7189400B2 (en) * | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US6576744B1 (en) * | 1998-09-23 | 2003-06-10 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
| BR0008772B1 (pt) | 1999-03-09 | 2011-11-01 | vetor de expressão, célula bacteriana ou fúngica cultivada, processos para expandir in vitro células hematopoiéticas e progenitores de células hematopoiéticas, e para detectar a presença de rna de ligando zalfa11 e de ligando zalfa 11 in vitro em uma amostra biológica. | |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| AU5142300A (en) | 1999-05-18 | 2000-12-05 | Millennium Pharmaceuticals, Inc. | Il-9/il-2 receptor-like molecules and uses thereof |
| AU2001253127A1 (en) * | 2000-04-05 | 2001-10-23 | Zymogenetics Inc. | Soluble zalpha11 cytokine receptors |
| AU2001263088B2 (en) | 2000-05-11 | 2006-07-20 | Genetics Institute, Llc. | Mu-1, member of the cytokine receptor family |
| EP2130919A1 (en) * | 2001-11-05 | 2009-12-09 | ZymoGenetics, Inc. | IL-21 antagonists |
| US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| EP1531850B1 (en) * | 2002-06-07 | 2012-02-22 | ZymoGenetics, Inc. | Use of IL-21 and monoclonal antibody for treating solid cancers |
| EA011686B1 (ru) * | 2002-07-15 | 2009-04-28 | Уайт | Способ модуляции развития и функций т-клеток-хелперов |
| KR20050119120A (ko) * | 2003-03-14 | 2005-12-20 | 와이어쓰 | 인간 ⅰｌ-21 수용체에 대한 항체 및 그것의 용도 |
| CN1849131A (zh) * | 2003-03-21 | 2006-10-18 | Wyeth公司 | 用白介素－21/白介素－21受体的激动剂治疗免疫性疾病 |
| EP1670501A2 (en) * | 2003-09-25 | 2006-06-21 | ZymoGenetics, Inc. | Methods of treating autoimmune diseases using il-21 |
| AU2005244942A1 (en) * | 2004-05-19 | 2005-12-01 | Wyeth | Modulation of immunoglobulin production and atopic disorders |
| JP2008508885A (ja) | 2004-08-05 | 2008-03-27 | ワイス | インターロイキン−２１受容体活性を中和すること |
| CN101052419A (zh) * | 2004-08-05 | 2007-10-10 | 惠氏公司 | 拮抗白介素－21受体活性 |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| WO2008081198A1 (en) | 2007-01-05 | 2008-07-10 | Imperial Innovations Ltd | Blood assays for predicting inflammatory responses |
-
2009
- 2009-05-22 PE PE2009000719A patent/PE20100141A1/es not_active Application Discontinuation
- 2009-05-22 AR ARP090101847A patent/AR071885A1/es not_active Application Discontinuation
- 2009-05-23 SA SA109300315A patent/SA109300315B1/ar unknown
- 2009-05-25 TW TW098117296A patent/TW201000129A/zh unknown
- 2009-05-25 CL CL2009001284A patent/CL2009001284A1/es unknown
- 2009-05-26 EP EP09751751A patent/EP2297199A1/en not_active Withdrawn
- 2009-05-26 CN CN200980128968XA patent/CN102105491A/zh active Pending
- 2009-05-26 NZ NZ589330A patent/NZ589330A/xx not_active IP Right Cessation
- 2009-05-26 AU AU2009248809A patent/AU2009248809A1/en not_active Abandoned
- 2009-05-26 JP JP2011510744A patent/JP2011523849A/ja active Pending
- 2009-05-26 US US12/472,209 patent/US8163884B2/en not_active Expired - Fee Related
- 2009-05-26 MX MX2010012811A patent/MX2010012811A/es active IP Right Grant
- 2009-05-26 KR KR1020107028877A patent/KR20110040773A/ko not_active Withdrawn
- 2009-05-26 WO PCT/US2009/045182 patent/WO2009143523A1/en not_active Ceased
- 2009-05-26 CA CA2724915A patent/CA2724915A1/en not_active Abandoned
- 2009-05-26 MY MYPI2010005509A patent/MY149448A/en unknown
- 2009-05-26 RU RU2010152690/10A patent/RU2010152690A/ru not_active Application Discontinuation
-
2010
- 2010-11-15 IL IL209328A patent/IL209328A0/en unknown
- 2010-11-19 ZA ZA2010/08335A patent/ZA201008335B/en unknown
- 2010-12-22 CO CO10160884A patent/CO6382184A2/es not_active Application Discontinuation
-
2012
- 2012-04-23 US US13/453,090 patent/US20120264919A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PE20100141A1 (es) | 2010-02-22 |
| MY149448A (en) | 2013-08-30 |
| IL209328A0 (en) | 2011-01-31 |
| EP2297199A1 (en) | 2011-03-23 |
| TW201000129A (en) | 2010-01-01 |
| CL2009001284A1 (es) | 2009-11-27 |
| CA2724915A1 (en) | 2009-11-26 |
| SA109300315B1 (ar) | 2012-08-28 |
| KR20110040773A (ko) | 2011-04-20 |
| AU2009248809A1 (en) | 2009-11-26 |
| JP2011523849A (ja) | 2011-08-25 |
| US20120264919A1 (en) | 2012-10-18 |
| MX2010012811A (es) | 2011-05-19 |
| RU2010152690A (ru) | 2012-06-27 |
| ZA201008335B (en) | 2014-04-30 |
| CN102105491A (zh) | 2011-06-22 |
| US20090298167A1 (en) | 2009-12-03 |
| US8163884B2 (en) | 2012-04-24 |
| NZ589330A (en) | 2012-12-21 |
| WO2009143523A1 (en) | 2009-11-26 |
| CO6382184A2 (es) | 2012-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071885A1 (es) | Proteinas de union al receptor de interleuquina 21 | |
| AR059604A1 (es) | Anticuerpos contra il- 22 humana y usos para los mismos | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| BR112019021991A2 (pt) | Proteínas de ligação ao antígeno trem2 e seus usos | |
| EP2352523A4 (en) | IMPROVED ANTI-CD19 ANTIBODIES | |
| PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
| BR112012018914A2 (pt) | "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica." | |
| AR063090A1 (es) | Proteinas de union al antigeno del receptor de la il-17 | |
| CO6280541A2 (es) | Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40 | |
| EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
| CO6710903A2 (es) | Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo | |
| EA201000471A1 (ru) | Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин | |
| EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
| PH12016501691A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| CO6270368A2 (es) | Anticuerpos o proteinas funcionales que comprenden una porcion de enlace de antigeno para un objetivo en el polipeptido esclerotina y sus composiciones | |
| MX2009013824A (es) | Proteinas de enlace de antigeno que enlazan par-2. | |
| CL2011000308A1 (es) | Anticuerpo monoclonal que se une al gen 3 de la activacion linfocitaria (lag-3) humana; composicion que comprende dicho anticuerpo; molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que lo comprende; metodo de preparacion; y su uso para estimular la respuesta inmune. | |
| MA32982B1 (fr) | Proteines de liaison au recepteur cgrp humain | |
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| EP3255063A3 (en) | Antibodies to matrix metalloproteinase 9 | |
| WO2011063003A3 (en) | Peptides and methods for the detection of lyme disease antibodies | |
| BR112014010161A2 (pt) | anticorpo monoclonal antiproteína de ligação ao dna tar de 43 kda (tdp-43) e seus método de preparação e uso no tratamento de proteinopatia tdp-43, bem como composições, polinucleotídeo, método in vitro e kit para diagnosticar proteinopatia tdp-43 | |
| EA200801621A1 (ru) | Антитела, направленные на her-3, и их применение | |
| AR072000A1 (es) | Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |